Gettinger S, et al. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. Abstract OA14.04. WCLC 7-10 sept. 2019, Barcelona, Spanje.
Ingebouwde lichtschakelaar laat CAR T-cellen op commando imuunmodulatoren produceren
mei 2022 | Dermato-oncologie, Immuuntherapie